Website Search
ID 15054

Restoring hope with Gleevec, Brian Druker

Interviewee: Brian Druker. Brian Druker talks about how Gleevec has restored patients' hope for the future. (DNAi Location: Applications > Genes and medicine > Drug design > Brian Druker > Restoring hope)
My commitment was to go back into the laboratory and develop something that could give people hope, restore their futures. And that's what we've accomplished with Gleevec\u2122 and so now instead of talking to people about well you only have a little while left to live and we're gonna have to give you high doses of chemotherapy with all these long list of toxicity, we're giving people a pill and they're feeling well and they have their hope restored for the future.
chronic myeloid leukemia,brian druker,restoring hope,gleevec,location applications,dnai,interviewee,cml,leukemia,chemotherapy,genes,toxicity,futures,cancer,medicine
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15056. Approval for Gleevec in record time, Brian Druker
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
15042. The first day of clinical trials for Gleevec, Bud and Yvonne
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
15714. Brian Druker
Brian Druker is a professor at Oregon Health Sciences University.
15712. Bud and Yvonne
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevec™ inhibits the molecular cause of chronic myeloid leukemia.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationPublic EventsNewsstandPartner With UsGiving